66 related articles for article (PubMed ID: 36576430)
1. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
Cowey CL
Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K; Osawa T; Kojima T; Hara T; Eto M; Takeuchi A; Nakai Y; Ueda K; Ozawa M; Uemura M; Ohba K; Tamura K; Shindo T; Nakagomi H; Takahashi A; Anai S; Yokomizo A; Morizane S; Kimura T; Shimazui T; Miyauchi Y; Mitsuzuka K; Hara H; Yoshimura K; Shiina H; Ito YM; Murai S; Nishiyama H; Shinohara N; Kitamura H;
Urol Oncol; 2023 Nov; 41(11):458.e9-458.e19. PubMed ID: 37798145
[TBL] [Abstract][Full Text] [Related]
4. Tivozanib in renal cell carcinoma: a new approach to previously treated disease.
Salgia NJ; Zengin ZB; Pal SK
Ther Adv Med Oncol; 2020; 12():1758835920923818. PubMed ID: 32547647
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Johns AC; Campbell MT; Gao M; Hahn AW; Lim Z; Wang E; Gao J; Shah AY; Msaouel P; Tannir NM
Oncologist; 2024 Mar; ():. PubMed ID: 38478923
[TBL] [Abstract][Full Text] [Related]
6. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms.
Jiang H; Liao J; Wang L; Jin C; Mo J; Xiang S
Front Immunol; 2023; 14():1163967. PubMed ID: 37325670
[TBL] [Abstract][Full Text] [Related]
7. Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
Narayan V; Haas NB
Int J Nephrol Renovasc Dis; 2016; 9():65-72. PubMed ID: 27099525
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.
Honma N; Inoue T; Tsuchiya N; Koizumi A; Yamamoto R; Nara T; Kanda S; Huang M; Numakura K; Saito M; Narita S; Satoh S; Habuchi T
Health Sci Rep; 2020 Dec; 3(4):e197. PubMed ID: 33088925
[TBL] [Abstract][Full Text] [Related]
9. Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.
Kudo M; Kang YK; Park JW; Qin S; Inaba Y; Assenat E; Umeyama Y; Lechuga MJ; Valota O; Fujii Y; Martini JF; Williams JA; Obi S
Liver Cancer; 2018 May; 7(2):148-164. PubMed ID: 29888205
[TBL] [Abstract][Full Text] [Related]
10. Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.
Socola F; Loaiza-Bonilla A; Benedetto P
Case Rep Oncol Med; 2012; 2012():390702. PubMed ID: 23326741
[TBL] [Abstract][Full Text] [Related]
11. Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers.
Aguilar K; Sharma AK; Yang T; Mehta D; Panda CS; Lokeshwar VB
J Cell Signal; 2024; 5(2):51-56. PubMed ID: 38726221
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.
Sakellakis M; Zakopoulou R
Cureus; 2023 Mar; 15(3):e35675. PubMed ID: 37012938
[TBL] [Abstract][Full Text] [Related]
13. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract][Full Text] [Related]
15. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
[TBL] [Abstract][Full Text] [Related]
17. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
